hsa-mir-1292: Hsa-mir-1292 is a microRNA that has been found to target lnc-AL355149.1-1, lnc-ZNF674-1, and hsa-mir-3613 [PMC4009106]. It has been shown to be highly expressed in individuals, with a log2 intensity of 7.5 [PMC3117799]. Hsa-mir-1292 is significantly upregulated in females and has a 1.63 to 1.94 fold-change in intensity levels [PMC3117799]. It is one of the miRNAs that are related to cancer prognosis or diagnosis, specifically for stomach adenocarcinoma (STAD) [PMC6856753]. Hsa-mir-1292, along with other miRNAs such as hsa-mir-509-2 and hsa-mir-2115, may serve as potential diagnostic biomarkers for STAD [PMC6856753]. In addition, hsa-mir-1292 has been found to be dysregulated between STAD tumor and paracancerous tissues [PMC6856753]. It is one of the miRNAs that are differentially expressed in SW480/STAT3-siRNA cells compared to SW480/siRNA-control cells [PMC4121995]. Hsa-mir-1292 has also been found to have aberrant methylation on the CGI shores of its promoter region [PMC4350105]. References: [PMC4009106] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009106/ [PMC3117799] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117799/ [PMC6856753] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856753/ [PMC4121995] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121995/ [PMC4350105] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350105/